Monoklonal Antikor (Hedef Ajan) Kullanan Kanser Hastalarının Semptom Sıklıkları Ve Yaşam Kalitelerinin İncelenmesi
Examination of Symptom Frequency and Quality of Life of Cancer Patients Using Monoclonal Antibody (Target Agent)
Yazar: Okçin, Figen
Dergi: Adıyaman Üniversitesi Sağlık Bilimleri Dergisi, Vol. 4 No. 3, 2018
Anahtar kelimeler: Health Care Administration ; Sağlık Kurumları Yönetimi ; monoklonal antikor,kanser,yaşam kalitesi,semptom ; monoclonal antibody,cancer,quality of life,symptom

Amaç:Monoklonal antikorlar (hedef ajan) son yıllarda pekçok hastalığın tedavisindekullanılmaktadır. Kanserli hastaların tedavisinde de  yaygın olarak kullanılmaya başlanılan builaçlar başarılı sonuçlar göstermektedir. Bu çalışmanın amacı monoklonalantikor kullanan kanserli hastaların semptom sıkları ve yaşam kalitelerininincelenmesidir. Yöntem: 28 Şubat- 31 Mayıs 2017  tarihleri arasında kemoterapi ünitesinebaşvuran, 18 yaşından büyük olan, 103 hasta ile görüşülmüştür. Hasta SoruFormu, Memorial Semptom Değerlendirme Skalası (MSAS), ve Yaşam Kalitesi İndeksi–Kanser Versiyonu-III (Quality of Life Index–Cancer Version-III (QOL-CV) )kullanılmıştır. Bulgular: Katılımcıların %70.9’u kadın, %30.1’i ilkokulmezunu, %74.8’i evli, %85.4’ü çalışmayan bireylerdir. Hastaların total MSASpuanı 0.69, QOL toplam ölçek puanı 22.15 olarak hesaplanmıştır. MSAS- Fizikselalt boyut puanı ile eğitim ve monoklonal çeşitleri arasında ilişkisaptanmıştır. QOL toplam ve alt boyutlarının pek çok bağımsz değişken  ile arasında anlamlı bir ilişki bulunmuştur. Sonuç:  Monoklonal antikor kullanan kanserhastalarının semptomlarla ilgili sıklık, şiddet ve sıkıntıları arttığında yaşam kalitelerinde nispeten olumsuz değişikliklergörülmektedir.

Aim : Monoclonal antibodies (target agent) have been used in the treatment of many diseases in recent years. These drugs, which have been widely used in the treatment of cancer patients, show successful results. The aim of this study is to examine the symptom frequencies and quality of life of cancer patients using monoclonal antibodies.Method: Between February 28 and May 31, 2017, 103patients, aged 18 years or older, who were referred to the chemotherapy unit,were interviewed. Patient Questionnaire, Memorial Symptom Assessment Scale(MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV) were used.Findings: 70.9% of the participants were women, 30.1% were primary schoolgraduates, 74.8% were married and 85.4% were not working. Total MSAS score ofthe patients was calculated as 0.69, QOL total scale score was 22.15. MSAS-Physical subscale score  and education and monoclonal varieties. QOL totaland sub-dimensions were found to be significantly correlated with manyindependent variables.   Result: Cancer patients using monoclonal antibodies have relatively negativechanges in their quality of life when the incidence, severity, and frequency ofsymptoms increase.: Monoclonal antibodies (target agent) have been used inthe treatment of many diseases in recent years. These drugs, which have beenwidely used in the treatment of cancer patients, show successful results. Theaim of this study is to determine the frequency of symptoms and the quality oflife of cancer patients using monoclonal antibodies. Method: Between February28 and May 31, 2017, 103 patients, aged 18 years or older, who were referred tothe chemotherapy unit, were interviewed. Patient Questionnaire Memorial SymptomAssessment Scale (MSAS), and Quality of Life Index-Cancer Version-III (QOL-CV)were used. Conclusion: 70.9% of theparticipants were women, 30.1% were primary school graduates, 74.8% weremarried and 85.4% were not working. Total MSAS score of the patients wascalculated as 0.69, QOL total scale score was 22.15. MSAS- Physical subscalescore  and education and monoclonal varieties. QOL total andsub-dimensions were found to be significantly correlated with many independentvariables.   Result:  Cancer patients using monoclonal antibodieshave relatively negative changes in their quality of life when the incidence,severity, and frequency of symptoms increase.